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Abstract: The hypoglycemic effect of Momordica charantia (Karela) has been reported from many laboratories. To 
our knowledge, the underlying biochemical mechanism of action of this important clinical effect has not been 
reported. During the course of investigation of this aspect of the herbal fruit, it was reported from our laboratory that 
ethanolic extract of Momordica charantia suppressed gluconeogenesis in normal and streptozotocin (STZ) induced 
diabetic rats by depressing the hepatic gluconeogenic enzymes fructose-1,6-bisphosphatase and glucose-6-
phosphatase. The herbal extract had also enhanced the activity of glucose-6-phosphate dehydrogenase, the rate-
limiting enzyme of hexose monophosphate shunt (a pathway for the oxidation of glucose). 
 





According to World Health Organization (WHO), 
medicinal plants are an accessible, affordable and 
culturally appropriate source of primary health care for 
more than 80% of Asia’s population [1]. Despite all the 
progress in synthetic chemistry and biotechnology, 
plants are still an indispensable source of medicinal 
preparations, both preventive and curative. Hundreds of 
species are recognized as having medicinal values and 
many of those are commonly used to treat and prevent 
specific ailments and diseases [2]. Momordica 
charantia (called bitter melon or bitter gourd in English 
or Karela in Bangla) is a tropical and subtropical vine 
of the family Cucurbitaceae, widely grown in Asia, 
Africa and the Caribbean for its edible fruit, which is 
among the most bitter of all fruits, is one of the well 
known medicinal plants. 
This herbaceous, tendril-bearing vine grows to 5 
meters. It bears simple, alternate leaves 4–12cm across, 
with 3–7 deeply separated lobes. Each plant bears 
separate yellow male and female flowers. In the 
Northern Hemisphere, flowering occurs during June to 
July and fruiting during September to November. As 
the fruit ripens, the flesh becomes tougher, bitterer, and 
too distasteful to eat. On the other hand, the pith 
becomes sweet and intensely red; it can be eaten 
uncooked in this state and is a popular ingredient in 
some Southeast Asian salads. When the fruit is fully 
ripe it turns orange and mushy and splits into segments 
which curl back dramatically to expose seeds covered 
in bright red pulp. 
The plant contains several biologically active 
compounds, chiefly momordicin I and II, and 
cucurbitacin B [3]. The plant contains also several bio-
active glycosides (including momordin, charantin, 
charantosides, goyaglycosides, momordicosides) and 
other terpenoid compounds (including momordicin-28, 
momordicinin, momordicilin, momordenol and 
momordol) [4-8]. It also contains cytotoxic (ribosome-
inactivating) proteins such as momorcharin and 
momordin [9].  
In 1962, Lolitkar and Rao extracted from the plant 
a substance, which they called charantin, which had a 
hypoglycemic effect on normal and diabetic rabbits 
[10]. Another principle, active only on diabetic rabbits, 
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was isolated by Visarata and Ungsurungsie in 1981 
[11]. Bitter melon has been found to increase insulin 
sensitivity [12]. In 2007, a study by the Philippine 
Department of Health determined that a daily dose of 
100mg/kg of body weight is compared to 2.5mg/kg of 
the anti-diabetes drug glibenclamide taken twice per 
day [13]. Tablets of bitter melon extract are sold in the 
Philippines as a food supplement under the trade name 
Charantia and exported to many countries [13]. 
Bitter melon also contains a lectin that has insulin-
like activity due to its non-protein-specific linking 
together to insulin receptors. This lectin lowers blood 
glucose concentrations by acting on peripheral tissues 
and similar to insulin's effects in the brain, suppressing 
appetite. This lectin is likely a major contributor to the 
hypoglycemic effect that develops after eating bitter 
melon [14]. 
 
2. Materials and Methods 
 
2.1 Experimental design 
40 male Long Evans rats, purchased from 
Bangladesh Institute of Research and Rehabilitation in 
Diabetes, Endocrine and Metabolic Disorder 
(BIRDEM) and International Centre for Diarrhoeal 
Disease Research, Bangladesh (ICDDR, B), were used 
to carry out this investigation. All the rats were divided 
into eight groups of five rats in each group. Group I was 
normal (fed), Group II was normal (18 hours fasting), 
Group III was diabetic (Streptozotocin (STZ) induced) 
control, Group IV was STZ-induced diabetic rats feed 
with ethanolic extract of Momordica charantia 
(200mg/kg body weight), Group V was STZ-induced 
diabetic rats treated with oral hypoglycemic drug 
(Dicon, 25mg/kg body weight), Group VI was STZ-
induced diabetic rats treated with rapid acting insulin 
(Actrapid, 20 units/kg body weight), Group VII was 
STZ-induced diabetic rats treated together with extract 
of Momordica charantia and drug and Group VIII was 
STZ-induced diabetic rats treated together with extract 
of Momordica charantia orally and insulin 
intravenously. 
 
2.2 Source of Momordica charantia 
Momordica charantia was purchased from Ananda 
Bazar near Fazlul Haq, Hall of Dhaka University, 
Dhaka. 
 
2.3 Preparation of 95% ethanolic extract of 
Momordica charantia 
The fresh vegetable (1 kg) was thoroughly washed 
in tap water, cut and the seeds were removed manually. 
The seedless vegetable was blended with 3 liters of 
95% (v/v) ethanol in a blender and kept at room 
temperature in a flat bottom flask for 48 hours with 
occasional shaking. The suspension was then filtered 
and the residue discarded. The alcoholic portion of the 
filtrate was evaporated in a rotavapor at 40-45°C under 
reduced pressure. Water was removed by lyophilizer. A 
yellowish semisolid material was obtained which 
weighed about 20 grams. 
 
2.4 Induction of diabetes 
Streptozotocin (STZ), an anti-tumor agent obtained 
from the fungus Streptomyces achromogenes, is widely 
used to produce diabetes in experimental animals. It 
induces diabetes by selectively destroying the β-cells of 
the islets of Langerhans of the pancreas which secrete 
insulin. There are some other diabetogenic agents such 
as alloxan, which also induces diabetes by damaging 
insulin-secreting cells. In our experiments, STZ was 
used to induce diabetes as the mortality rate is lower 
with this drug. STZ was dissolved in physiological 
saline previously adjusted to pH 4.3 with 0.05M citric 
acid. This solution was administered by intravenous 
injection (through tail vein) to 18 hrs fasted rats at a 
dose of 60mg/kg body weight. 
 
2.5 Oral administration of Momordica charantia 
 2.0g of semisolid alcohol-soluble material of 
ethanolic extract of Momordica charantia obtained was 
dissolved in water and this suspension was fed orally to 
the experimental rats at a dose of 200mg/kg body 
weight. 
 
2.6 Collection of blood tissue samples 
Before and after inducing the rats with STZ to 
become diabetic, blood was drawn by cutting the end of 
the tail (by tail blotting) using surgical scissors. After 
90 minutes of oral administration of an aqueous 
suspension of plant extract, blood was collected by 
sacrificing the rats using a scalpel. Na-heparin was used 
as an anticoagulant and NaF was used as glycolysis 
inhibitor. Before cutting the tail end, the tail of each rat 
was kept in warm water (40°C) for 30 seconds and 
blood was drawn immediately into a small test tube. 
Livers were surgically removed immediately after 
sacrificing the animals and taken into glass beakers 
containing ice-cold saline. 
 
2.7 Storage of blood sample and liver sample 
Some portion of blood was immediately used to 
estimate glucose levels. Other portions of blood were 
stored at 4°C until used. Livers were stored at -4°C. 
 
2.8 Estimation of blood glucose 
For glucose estimation, a reagent kit, supplied from 
Randox Laboratories Ltd., was used. Blood glucose was 
estimated by the glucose oxidase-peroxidase (GOD-
POD) methods of Trinder. 
 
2.9 Assay of hepatic glucose-6-phosphate 
dehydrogenase 
Glucose-6-phosphate dehydrogenase activity in 
hepatocytes was assayed by the method of Lohr and 
Waller. A slight modification of this procedure was 
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made where Triethanolamine buffer was replaced by 
Tris-HCl buffer. 
 
2.10 Assay of hepatic fructose-1,6-bisphosphatase 
Fructose-1,6-bisphosphatase activity in hepatocytes 
was assayed by the method of Pogell and McGilvery in 
which inorganic phosphate liberated from Fructose-1,6-
bisphosphate was determined. In the present work, the 
procedure is slightly modified. 
 
2.11 Assay of hepatic glucose-6-phosphatase 
Hepatic glucose-6-phosphatase was assayed by 
the method of Baginsky et al., which involves the 
estimation of inorganic phosphate liberated from 
glucose-6-phosphate by this enzyme. In the present 
work, the procedure was slightly modified. 
 
 
3. Results and Discussion 
 
It was shown from our experiments that oral 
administration of the ethanolic extract of Momordica 
charantia (Karela) to rats lowered blood glucose level 
by suppressing gluconeogenesis by inhibition of the key 
hepatic gluconeogenic enzymes, glucose-6-phosphatase 
and fructose-1,6-bisphosphate dehydrogenase and 
stimulating glucose oxidation by the pentose phosphate 
pathway through activation of glucose-6-phosphate 
dehydrogenase, the rate-limiting enzyme of this 
pathway. These mechanisms of action of the extract 
were shown only at the enzymatic levels. But no 
investigation was carried out on the mechanism of 
action of the extract at the hormonal levels. 
In an effort to shed light on the hypoglycemic 
effects of the extract, the current investigation was 
undertaken. For this, both insulin and the well known 
oral hypoglycemic agent namely glibenclamide (locally 
known as dicon) were administrated with or without the 
herbal extract of STZ induced diabetic rats to examine 
this insulin-like effect of the herbal extract. 
It is clear from the results presented in Table 3.1 
that the levels of two rates limiting enzymes of the 
hepatic gluconeogenic pathway, glucose-6-phosphatase 
and fructose-1,6-bisphosphatase, are increased in STZ 
induced diabetic condition by 71.29% and 52.58%, 
respectively. Oral administration of 95% of ethanolic 
extract decreased significantly the activity of enzymes 
by 40.54% (Table 3.4) and 40.49% (Table 3.3). Dicon 
and insulin showed stronger effect the corresponding 
values in percent were 54.05, 48.0 and for insulin were 
59.73, 53.37. The effect of extracts was not significant 
(p<0.5) in dicon and insulin-treated rats. Possible 
mechanism of inhibition of the enzymes may be 
explained as follows: 
STZ is known to destroy the β-cells of islets of 
Langerhans of the pancreas. So, participation of insulin 
could be excluded. The extract might act by decreasing 
glucagon secretion or secondarily by blocking glucagon 
receptors in the plasma membrane. But this is not 
consistent with our finding because dicon (and insulin 
secretagogue) which was found to show hypoglycemic 
activity in STZ induced diabetic rats. 
Likewise/similarly extract would be expected to act in 
the same manner as dicon i.e. by secreting insulin in 
STZ induced rats. The extract might cause this 
inhibition directly by elevating the level of fructose-2,6- 
bisphosphate, which is a potent allosteric modulator of 
fructose-1,6-bisphosphatase. Glucose-6-phosphatase is 
also an irreversible gluconeogenic enzyme but not a 
regulatory enzyme. The possible mechanism of its 
decreased activity due to oral administration of the 
extract is not clear. 
Glucagon and insulin control glycolysis and 
gluconeogenesis by regulating the level of fructose-2,6-
bisphosphate at one of the most important key 
crossroads of glucose metabolism namely conversion of 
fructose-6-phosphate to fructose-1,6-bisphosphate. 
Insulin by virtue of its ability to lower cAMP raises 
fructose-2,6-bisphosphate which inhibits 
gluconeogenesis. On the contrary, glucagon by 
elevating the levels of cAMP lowers the level of 
fructose-2,6-bisphosphate and stimulates 
gluconeogenesis. Glucagon binds to its receptors in the 
plasma membrane and active the cAMP cascade which 
in turn produces active protein kinase that 
phosphorylates two enzymes phosphofructokinase-II 
and fructose-2,6-bisphosphatase. This phosphorylation 
inhibits phosphofructokinase-II and stimulates fructose-
2,6-bisphosphatase resulting in reduced levels of 
fructose-2,6-bisphosphate. Since fructose-2,6-
bisphosphate is a potent allosteric positive modulator of 
phosphofructokinase-II and potent inhibitor of fructose-
2,6-bisphosphate. The net effect of lowered levels of 
fructose-2,6-bisphosphate would be and onset of 
gluconeogenesis and inhibition of glycolysis. 
 
Table 2.1. Body weight (g) and blood glucose (mmol/l) levels of normal and streptozotocin (STZ) induced diabetic rats. 
 
Parameters assayed   Normal (fed) Normal (18hrs fasting rats) Diabetic 
Body weight (g) 
Before STZ injection Mean ± S.D. 186.2 ± 12.83 179.7 ± 12.18 - 
After STZ injection 
Mean ± S.D. - - 157.8 ± 16.98 
Effect (%) - - -11.88 
Sig. (p) - - p<0.05 
Blood glucose level 
(mmol/l) 
Before STZ injection Mean ± S.D. 6.34 ± 0.49 4.08 ± 0.18 - 
After STZ injection 
Mean ± S.D. - - 16.20 ± 0.90 
Effect (%) - - +297 
Sig. (p) - -  
Here, “+” indicates increase, “-” indicates decrease. 
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Table 3.1.  Hepatic glucose-6-phosphate dehydrogenase, glucose-6-phosphatase and fructose-1,6-bisphosphatase levels of normal and STZ 
induced rats. 
 
Parameters assayed Normal (18hrs fasting rats) Diabetic 
Glucose-6-phosphatedehydrogenase level 
(units/mg of protein) 
Mean ± S.D. 355.17 ± 9.97 302.4 ± 10.46 
Effect (%) - -14.84 
Sig. (p) - p < 0.001 
Glucose-6-phosphatase level 
(Units/mg of protein) 
Mean ± S.D. 2.16 ± 0.086 3.70  ± 0.193 
Effect (%) - +71.29 
Sig. (p) -  
Fructose-1,6-bisphosphatase level 
(Units/mg of protein) 
Mean ± S.D. 0.42 ± 0.07 0.65 ± 0.06 
Effect (%) - +52.58 
Sig. (p) - p < 0.001 
Here, “+” indicates increase, “-” indicates decrease. 
 
Table 3.2. Blood glucose levels (mmol/l) of streptozotocin-induced diabetic rats (before/after treatment) 
 
 Treatment Mean±S.D. Effect (%) Sig. (p) 
Sig p (Dicon vs. 
Extract + Dicon) 
Sig p (Insulin vs. 
Extract + Insulin) 
Diabetic (untreated) STZ injection 16.20 ± 0.90   
  
Diabetic (treated) 
Extract of Momordica charantia 
(200mg/kg body wt.) 12.90 ± 1.15 -20.37 p<0.001 
Dicon (25mg/kg body wt.) 3.92 ± 0.56 -75.80 - 
Insulin (20units/kg body wt.) 2.82 ± 0.31 -82.59 - 
Extract (200mg/kg body wt.) + 
Dicon (25mg/kg body wt.) 6.42 ± 0.95 -60.37 - p<0.001  
Extract (200mg/kg body wt.) + 
Insulin (20units/kg body wt.) 4.22 ± 0.77 -73.59 -  p<0.01 
Here, “+” indicates increase, “-” indicates decrease. 
 
Table 3.3. Hepatic fructose-1,6-bisphosphatase (units/mg of protein) levels of streptozotocin induced diabetic rats (before/after treatment). 
 
 Treatment Mean±S.D. Effect (%) 
Sig. 
(p) 
Sig p (Dicon vs. 
Extract + Dicon) 
Sig p (Insulin vs. 
Extract + Insulin) 
Diabetic (untreated) STZ injection 0.65 ± 0.061 - - 
  
Diabetic (treated) 
Extract of Momordica charantia 
(200mg/kg body wt.) 0.388 ± 0.046 -40.49 p<0.001 
Dicon (25mg/kg body wt.) 0.338 ± 0.037 -48.00 - 
Insulin (20units/kg body wt.) 0.304 ± 0.043 -53.37 - 
Extract (200mg/kg body wt.) + 
Dicon (25mg/kg body wt.) 0.360 ± 0.047 -44.48 - p<0.50  
Extract (200mg/kg body wt.) + 
Insulin (20units/kg body wt.) 0.320 ± 0.022 -50.92 -  p<0.50 
Here, “+” indicates increase, “-” indicates decrease 
 
Table 3.4. Hepatic glucose-6-phosphatase (units/mg of protein) levels of streptozotocin-induced diabetic rats (before/after treatment). 
 
 Treatment Mean ± S.D. Effect(%) Sig. (p) Sig p (Dicon vs. Extract +Dicon) 
Sig p (Insulin vs. 
Extract + Insulin) 
Diabetic (untreated) STZ injection 3.70 ± 0.193 - - 
  
Diabetic (treated) 
Extract of Momordica charantia 
(200mg/kg body wt.) 2.20 ± 0.035 -40.54 p<0.001 
Dicon (25mg/kg body wt.) 1.70 ± 0.108 -54.05  
Insulin (20units/kg body wt.) 1.49 ± 0.019 -59.73  
Extract (200mg/kg body wt.) + 
Dicon (25mg/kg body wt.) 1.84 ± 0.143 -50.27  p<0.5  
Extract (200mg/kg body wt.) + 
Insulin (20units/kg body wt.) 1.56 ± 0.08 -57.83   p<0.1 
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Table 3.5. Hepatic glucose-6-phosphate dehydrogenase (units/mg of protein) levels of streptozotocin-induced diabetic rats (before/after 
treatment). 
 
 Treatment Mean ± S.D. Effect (%) Sig. (p) 
Sig p (Dicon vs. 
Extract + Dicon) 
Sig p (Insulin vs. 
Extract + Insulin) 
Diabetic (untreated) STZ injection 302.45 ±10.46 - - 
  
Diabetic (treated) 
Extract of Momordica charantia 
(200mg/kg body wt.) 388.21 ± 21.76 +28.45 p<0.001 
Dicon (25mg/kg body wt.) 478.32 ± 21.65 +58.15  
Insulin (20units/kg body wt.) 499.28 ±26.64 +65.08  
Extract (200mg/kg body wt.) + 
Dicon (25mg/kg body wt.) 455.08 ± 22.26 +50.46  p<0.5  
Extract (200mg/kg body wt.) + 
Insulin (20units/kg body wt.) 489.49 ± 18.66 +61.84   p<0.5 
Here, “+” indicates increase, “-” indicates decrease 
 
Form the above discussion it appears that the 
hypoglycemic effect caused by Momordica charantia is 
partially mediated through the decrease production of 
glucose by the process of gluconeogenesis in the liver. 
Furthermore, it is evident from the results 
represented in Table 2.1, 3.1, 3.2 and 3.5 STZ diabetes 
elevated the blood glucose level by 297% and 
depressed the activity of liver glucose-6-phosphate 
dehydrogenase by 14.84% (p<0.001). The ethanolic 
extract of Momordica charantia depressed the level of 
glucose by 20.37% (p<0.001) and elevated the activity 
of hepatic glucose-6-phosphate dehydrogenase by 
28.45% (p<0.001). Dicon and insulin showed the 
similar effects qualitatively but much larger 
quantitatively. 
The possible mechanisms of this hypoglycemic 
effect of extract in rats may be explained as follows:  
a)  Suppression of the key hepatic gluconeogenic 
enzymes, glucose-6-phosphatase and fructose-
1,6-bisphosphatase. Due to the depressed activity 
of these enzymes, the glucose synthesis would 
decrease and as a result, blood glucose level 
would be reduced.  
b)  Elevation in the activity of glucose-6-phosphate 
dehydrogenase, the hexose monophosphate 
(HMP) shunt enzyme. The increased activity of 
this regulatory enzyme of the HMP pathway 
reflects an increased glucose oxidation through 
this pathway and thus contributes partially to the 
overall blood glucose decreasing effect of the 




From the results described above, it is clear that the 
effect of the extract on the parameters assayed is 
significant in the absence of dicon or insulin while the 
effect is insignificant in the presence of them (dicon 
and insulin). That is, the effect of extract, dicon or 
insulin-treated animals are non-additive. The results 
that are described and discussed above suggest that the 
active hypoglycemic principle(s) in the herbal extract 
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